Robeco Institutional Asset Management B.V. Lowers Stock Position in Solventum Corporation $SOLV

Robeco Institutional Asset Management B.V. decreased its position in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 72.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,619 shares of the company's stock after selling 22,619 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Solventum were worth $654,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Solventum by 0.7% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company's stock worth $1,500,000 after buying an additional 140 shares during the last quarter. Tradition Wealth Management LLC grew its position in shares of Solventum by 1.6% in the first quarter. Tradition Wealth Management LLC now owns 8,830 shares of the company's stock valued at $671,000 after purchasing an additional 143 shares during the period. Perigon Wealth Management LLC grew its position in shares of Solventum by 3.8% in the first quarter. Perigon Wealth Management LLC now owns 4,352 shares of the company's stock valued at $331,000 after purchasing an additional 159 shares during the period. SouthState Corp grew its position in shares of Solventum by 31.9% in the first quarter. SouthState Corp now owns 699 shares of the company's stock valued at $53,000 after purchasing an additional 169 shares during the period. Finally, HB Wealth Management LLC lifted its stake in shares of Solventum by 5.6% in the second quarter. HB Wealth Management LLC now owns 3,463 shares of the company's stock worth $263,000 after buying an additional 185 shares in the last quarter.

Solventum Stock Up 0.3%

Shares of Solventum stock opened at $72.39 on Thursday. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92. The company has a market cap of $12.55 billion, a P/E ratio of 33.51, a PEG ratio of 2.94 and a beta of 0.50. The firm has a fifty day moving average of $72.77 and a two-hundred day moving average of $72.16.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, topping analysts' consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business had revenue of $2.16 billion for the quarter, compared to analysts' expectations of $2.12 billion. During the same period in the prior year, the company posted $1.56 EPS. The business's revenue for the quarter was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on SOLV shares. Argus raised shares of Solventum from a "hold" rating to a "buy" rating and set a $90.00 price target on the stock in a research note on Tuesday, July 1st. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Solventum in a research note on Wednesday. Wall Street Zen downgraded shares of Solventum from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, September 9th. Jefferies Financial Group began coverage on shares of Solventum in a research report on Thursday, September 11th. They set a "hold" rating and a $80.00 price target for the company. Finally, Wells Fargo & Company lifted their price objective on shares of Solventum from $79.00 to $82.00 and gave the company an "equal weight" rating in a report on Monday, September 15th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.